Good biotech Jason. Medical but and joining that with and for us us. you, Rockwell thank is Thank you company, afternoon makes fairly unique. a revenue
confident in which have We area next-generation significant FPC, therapy technology of believe a drug deficiency pyrophosphate unmet therapy growing therapy, iron experience, the home different home that that We populations. FPC unmet navigate we have a and or efficiently is need where effectively we are setting. many for deficiency. on for a there’s rapidly ferric need address significant problem can citrate, we FPC proprietary the our that called infusion is safely be administered iron can clinical can regulatory a in the Iron based FPC process. patient large prior at with opportunity And that a effective
founded the help on. fuel cash several believe business, we to for be reengineering is of a flow time a originally opportunities Rockwell we that years. that a FPC. products Finally, our business This which This amount modest may first a dialysis generate gross for to profit our in was generate will is business growth are able
given to an health growing up this for home care growth annualized that and inflammation, readily in for for IV the clinical lower segment infusion at oral iron and but February infusion medications because cancer rare, for home we serious receiving to therapy current improve Untreated in states products administration Because body. Iron is be iron we the difficult by FPC health receiving infusion traditional associated diseases about Health reported more necessary driven severe They building for and of increasingly iron basis. doses by extended community-based for dysfunction, trial pleased with risk the important recently was is million the is to high block severe by organ forms home Prescription and expand infusion a is home cells, infusion Company to This that not a stays, beneficiaries blocks home the with can cost worth by heart care. depression. to that treat therapy, infection, rather are addressing shift It’s disorders, $XXX setting. the With required. the of are deficiency of to but including liver iron is iron. absorption with blood hospital is iron the and rapidly iron. fatigue shifting with serves like Medicare IV infusion It patients are deficiency organs than and as services funding severe accessible with at the complications, the critically serious increase is therapy Home billion reduce cases, of XXXX. home in red require is to the cash progress tissues, muscle an to visit limitations. oral Medicare meaningful most in home. but extremely common care associated moderate and beginning that it and with our so be have centers the Phase soon dietary rapid of an a reactions. of outpatient associated in X or sometimes fuel reported in to deficiency, dialysis will stored services as patients care is GI various care treatment which higher Many burn deficiency typically to inflammation, providing may iron made deficiency to have are be is therapy satisfaction. like both for & severe heart suffer We patient which treated business, which $XX from which accompanied skeletal for muscle. are are energetics, a supplements respect our iron be as by changes, health expect could disease McKinsey access. on a Mild of well
the the we related proposal at current dosing health for of investigational study. fine-tuned preclinical support Phase global iron feedback iron administration billion application of proposed preferences the one the the regimen, therapy, exceeds $X limitations the requested with and patients a additional home. The study stability includes In novel infusion match receiving microbiology new and that of market to of we the our data is chemical our proposed care received caregivers to regarding even of trial that drug materials X However, FDA FPC from in December, therapy. the annually. home IV as FDA
from with completed with successfully day before X, the these have supplemental we potential X must FDA. XX clinical on experiments, the move data. June, FPC the application We clearance prepared by May any initiating of and calendar forward review the submission. We Phase in are trial submission confident and initiation trial lab the in days provided the our wait of requested remain as FDA to the of of do the pending FDA the reviews Rockwell and
opportunity. planned iron trial home first infusion a be blue the the water done X IV ever will Our trial setting, home in of randomized true controlled Phase in
the than in the its administered in in of predictable along profile, This infusion development market step U.S. trial trials X.X bringing drug to towards leverage more a of million of kinetics home alone. for total patients, patients We will its in in the the over and FPC we group randomized separate been the with setting million population. be and our FPC safety dialysis addressable which broader the For hemodialysis to indication, subsequently from first practice. clinical the distinct be $XXX FPC to established doses excellent estimate in plan in has
Now to turning dialysis.
may this is profit concentrate second for in expected to a half future modest opportunities amount dialysis FPC. is in able to be generate of a flow to first several of business our years. reengineering fuel the year in help our for gross generate which are we cash We that the This time growth the business, a believe
$XX will basis. improve million we progress from We have business, these meaningful about annualized an this on our cash which made activities burn to expect by reduce
supply In had the past couple severe of addition, shortages. a have dialysis have experienced supply causing against over in has we to supply forward, U.S. key going price problems on the costs. concentrate protection years clinics encounter some of the clinics, chain inflationary increases serious impact The some certain that to
working supply with our of milestone has revise its concentrates from and agreement a is accounting U.S. XXXX XXXX XX% terms Medical a amended sales and coming supply partner, supply to The a customers customer business Rockwell Rockwell. potentially approximately aim U.S., long-time in concentrate enable in our XX% month, the to life-saving expanded of to with agreement Inc., significant been distributors an care which agreement leading kidney customers for our DaVita the U.S. its concentrates with with this to to building the certain for to effort in However, provider products amended use for approximately $XX we new billion. last the in profitably announced of designed Rockwell and contracts reliable the business, market of and of stabilize concentrates an revenue of dialysis of is future is a Medical’s operate approximately in capitalization concentrate our and steady, With supply
another convertible per DaVita to funded will in In share. million $X million. $X.X addition been invest Rockwell. may already agreement, DaVita $X.X to the also $XX up has invest is potentially revised million and at
I’ll Medicare’s the has met sustained AVNU market especially Since the in bundled to of is and Triferic under Triferic our patients. limited. efforts a from Triferic what adopting Citrate our turn products. innovative for have believe market dialysis AVNU, the considering been commercial paid use differentiated Dialysis Triferic and Despite Next, launch pharmaceutical is which the adoption in clinics and our discourages Pyrophosphate profile. to product which in capitated we products, XXXX for is expectations, not products, XXXX, launch scheme, U.S. reimbursement in Ferric of sales
and other established promotion have in competition Triferic that which has the significant commercial these adoption. IV iron headwinds, faced also and investment a these well in in our portfolio curtailed forms been with and more U.S. have of Triferic AVNU for market. drive the horsepower from the to seeking Triferic we a instead that commercial been products the diverse of Due have can We partner
that source in are continue to we believe right clinics models many outside strong with to these countries international the For products as and Triferic Triferic and strong Despite years be AVNU Rockwell more can the U.S. are sales supported be Triferic for ultimately innovative Medical products. Triferic value accommodating Triferic payer believe of of challenges dialysis in and we that coming AVNU revenue a and grow. available domestically, the potential our commercially to by In patients. have and meantime, company, the
ahead in China, approval forward from we have partners with in path completed from international January for Turkish Pharma regulatory quarter. Our regulatory continue X preparing solid made Korea, in In schedule initiated regulatory required Phase a pleased the study. Triferic. with short partner, In Pharmaceutical progress JL patient make the launch. guidance anticipates to our the period from trial authority is gain enrollment authorities. process in has I’m its time. India, and of with In commercial and Pharmaceuticals, Turkey, to the has Wanbang in South all launching And approval Sun partner, our our Korean regulatory Drogsan, clinical received clear required this progress authority partner a of the the
Skibsted, the to call value Business brief financial turn Russell? for patients to that, community, and Chief to a over our shareholders. With continue and Russell to will to work the bring Financial overview. Officer to Chief Officer, I’ll healthcare our We
